Patents Assigned to The Feinstein Institute for Medical Research
-
Publication number: 20090170951Abstract: Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.Type: ApplicationFiled: March 23, 2007Publication date: July 2, 2009Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventor: Yousef Al-Abed
-
Patent number: 7537908Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: December 1, 2005Date of Patent: May 26, 2009Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Publication number: 20080305120Abstract: The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specially, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation.Type: ApplicationFiled: June 16, 2005Publication date: December 11, 2008Applicants: MEDIMMUNE, INC., THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventors: Davorka Messmer, Kevin Tracey, Peter Kiener, Scott Alban
-
Publication number: 20080305118Abstract: Methods of treating a mammal having type 1 diabetes or a risk for type 1 diabetes are provided. The methods comprise administering to the mammal a pharmaceutical composition comprising an agent that inhibits MIF in the mammal. Also provided are methods of evaluating whether a compound is useful for preventing or treating type 1 diabetes. The methods comprise determining whether the compound inhibits a macrophage migration inhibitory factor (MIF) in a mammal, then, if the compound inhibits the MIF, determining whether the compound inhibits development of type 1 diabetes.Type: ApplicationFiled: March 29, 2005Publication date: December 11, 2008Applicant: The Feinstein Institute for Medical ResearchInventor: Yousef Al-Abed
-
Publication number: 20080249439Abstract: Described herein are devices, systems and method for treating inflammatory disorders by modulating a subject's inflammatory reflex. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject in a manner which significantly reduces proinflammatory cytokines in the subject and/or provides a therapeutically effective treatment for the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.Type: ApplicationFiled: March 13, 2008Publication date: October 9, 2008Applicant: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Howland Shaw Warren, Michael Allen Faltys
-
Patent number: 7413861Abstract: The present invention provides a method for predicting whether a patient having varicocele-associated infertility will have an increase in sperm in the ejaculate after varicocele repair surgery. In the method of the present invention, the present or absence of undelete forms of exons 6, 7, 8 and 9 the patient's L-VDCC ?1c transcript is detected. The presence of undeleted forms of the exons indicates that varicocele repair surgery will result in increased ejaculate, and the absence of undeleted forms of the exons indicates that varicocele repair surgery will not result in increased ejaculate.Type: GrantFiled: November 23, 2004Date of Patent: August 19, 2008Assignee: The Feinstein Institute for Medical ResearchInventors: Susan Benoff, Ian R. Hurley, Robert G. Pergolizzi, Leslie Goodwin
-
Publication number: 20080108058Abstract: The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.Type: ApplicationFiled: October 3, 2006Publication date: May 8, 2008Applicants: REGENTS OF THE UNIVERSITY OF MINNESOTA, Feinstein Institute for Medical ResearchInventors: Timothy W. Behrens, Emily C. Baechler, Peter K. Gregersen
-
Patent number: 7329643Abstract: Methods of inhibiting HMGB1 release by a mammalian cell are provided. The methods comprise treating the cell with sufficient fetuin to inhibit HMGB1 release. Methods of inhibiting an inflammatory cytokine cascade in a mammal are also provided. These methods comprise administering sufficient fetuin to the mammal to inhibit HMGB1 release in the mammal. Also provided are methods of treating a condition in a mammal characterized by an inflammatory cytokine cascade. These methods comprise administering sufficient fetuin to the mammal to inhibit HMGB1 release in the mammal.Type: GrantFiled: May 13, 2005Date of Patent: February 12, 2008Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haicho Wang, Andrew E. Sama
-
Patent number: 7316906Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: GrantFiled: August 2, 2002Date of Patent: January 8, 2008Assignee: The Feinstein Institute for Medical ResearchInventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil
-
Publication number: 20080004207Abstract: Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.Type: ApplicationFiled: February 6, 2007Publication date: January 3, 2008Applicants: University of pittsburgh of the Commonwealth System of Higher Education, The Feinstein Institute for Medical ResearchInventors: Allan Tsung, Timothy Billiar, Mitchell Fink, Kevin Tracey
-
Patent number: 7304034Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.Type: GrantFiled: November 20, 2002Date of Patent: December 4, 2007Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh-Of the Commonwealth System of Higher EducationInventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
-
Patent number: 7273872Abstract: Methods for inhibiting an inflammatory cytokine cascade in a patient are provided. The methods are directed to treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an ?7 nicotinic receptor.Type: GrantFiled: December 5, 2003Date of Patent: September 25, 2007Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Hong Wang
-
Patent number: 7238715Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor.Type: GrantFiled: September 30, 2004Date of Patent: July 3, 2007Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Hong Wang
-
Patent number: 7220723Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent that inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.Type: GrantFiled: June 6, 2003Date of Patent: May 22, 2007Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Huan Yang
-
Patent number: 7192917Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: November 21, 2003Date of Patent: March 20, 2007Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Patent number: 7186555Abstract: The present invention provides methods and pharmaceutical compositions of the human glycoprotein fetuin, or ?2-HS glycoprotein, or fragments thereof to mitigate tissue damage associated with ischemia, particularly in stroke or in myocardial infarction.Type: GrantFiled: April 13, 2000Date of Patent: March 6, 2007Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Patent number: 7179447Abstract: The present invention provides compositions for the treatment, inhibition or prevention of diseases or disorders, including cancer, immune diseases or disorders, and infectious diseases, comprising interferon-producing cells (IPCs) and methods of administering the IPCs. The present invention also provides compositions for the treatment, inhibition or prevention of diseases or disorders, including cancer, immune diseases or disorders, and infectious disease, comprising purified interferon (IFN) from IPCs and methods of administering the IFN. The present invention further provides methods for monitoring the progression of a disease or a disorder such as HIV infection or cancer, comprising measuring the abundance of IPCs in lymphoid organs or blood samples from a subject suffering from a disease or disorder.Type: GrantFiled: February 4, 2002Date of Patent: February 20, 2007Assignee: The Feinstein Institute for Medical ResearchInventors: Frederick P. Siegal, Michael Shodell
-
Patent number: 7151082Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: November 20, 2002Date of Patent: December 19, 2006Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Patent number: 7118865Abstract: The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.Type: GrantFiled: August 16, 2002Date of Patent: October 10, 2006Assignees: Regents of the University of Minnesota, The Feinstein Institute for Medical ResearchInventors: Timothy W. Behrens, Emily C. Baechler, Peter K. Gregersen
-
Patent number: 7097838Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: July 31, 2002Date of Patent: August 29, 2006Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang